Effect of a Glucosidase Inhibitor On The Bioactivity And Immunoreactivity of hUman Immunodeficiency Virus Type 1 Envelope Glycoprotein Free

Abstract

Apparently conflicting results have been reported regarding the role of env glycoprotein glycans in human immunodeficiency virus type 1 (HIV-1) infectivity and cytopathogenicity. Whereas we have shown that enzymic removal of carbohydrates from mature envelope glycoproteins has only limited effect on the ability of HIV-1 to bind to CD4 and to infect target cells, sugar analogues that interfere with the glycosylation process of the nascent molecule markedly reduce virus infectivity. Here we have investigated the effect of a glucosidase inhibitor, 1-deoxynojirimycin (dNM), on the bioactivity and immunoreactivity of precursor gp160 produced by recombinant vaccinia virus-infected BHK-21 cells (rgp160). dNM (4 m) did not affect the amount of rgp160 recovered nor its secretion from the cells. As described by other authors the effect of dNM was incomplete, resulting in the production of rgp160, the glycosylation of which was heterogeneous with respect to apparent distribution and to sensitivity to endoglycosidase H and endoglycosidase F, all the species being susceptible to -glycanase. A major reduction of the binding to CD4 cells was noted with rgp160 produced by dNM-treated cells using a quantitative indirect immunofluorescence assay and labelling with polyclonal human anti-HIV IgG. Similarly, dNM treatment altered the accessibility to murine monoclonal antibody 110-4 of the exposed V3 loop of HIV-1 gp120 by at least 10-fold, as determined by either ELISA capture assay or immunoaffinity purification. Such bioactivity and conformation modifications, which result from the abnormal folding of the nascent glycoprotein due to aberrant glycosylation, may account for the impaired HIV-1 infectivity elicited by dNM.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-72-8-1919
1991-08-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/72/8/JV0720081919.html?itemId=/content/journal/jgv/10.1099/0022-1317-72-8-1919&mimeType=html&fmt=ahah

References

  1. Alexander S., Elder J. H. 1984; Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science 226:1328–1330
    [Google Scholar]
  2. Alizon M., Wain-Hobson S., Montagnier L., Sonigo P. 1986; Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell 46:63–74
    [Google Scholar]
  3. Anderson O., Sorensen A. M., Svehag S., Fenouillet E. 1991; Conglutinin binds the HIV-1 envelope glycoprotein gp160 and inhibits its interaction with cell membrane CD4. Scandinavian Journal of Immunology 33:81–88
    [Google Scholar]
  4. Chakrabarti L., Guyader M., Alizon M., Daniel M. D., Desrosiers R. C., Tiollais P., Sonigo P. 1987; Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature, London 328:543–547
    [Google Scholar]
  5. Davis D., Stephens D. M., Willers C., Lachmann P. J. 1990; Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. Journal of General Virology 71:2889–2898
    [Google Scholar]
  6. Elbein A. D. 1987; Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. Annual Review of Biochemistry 56:497–534
    [Google Scholar]
  7. Fennie C., Lasky L. A. 1989; Model for intracellular folding of the human immunodeficiency virus type 1 gp120. Journal of Virology 63:639–646
    [Google Scholar]
  8. Fenouillet E., Fayet G., Hovsepian S., Bahraoui E., Ronin C. 1986; Immunochemical evidence for a role of complex carbohydrate chains in thyroglobulin antigenicity. Journal of Biological Chemistry 261:15153–15158
    [Google Scholar]
  9. Fenouillet E., Clerget-Raslain B., Gluckman J. C., Guetard D., Montagnier L., Bahraoui E. 1989; Role of JV-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Journal of Experimental Medicine 169:807–822
    [Google Scholar]
  10. Fenouillet E., Gluckman J. C., Bahraoui E. 1990; Role of JV-linked glycans of envelope glycoproteins in infectivity of HIV-1. Journal of Virology 64:2841–2848
    [Google Scholar]
  11. Freed E. O., Myers D. J., Risser R. 1990; Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proceedings of the National Academy of Sciences, U.S.A 87:4650–4654
    [Google Scholar]
  12. Geyer H., Holschbach C., Hunsmann G., Schneider J. 1988; Carbohydrates of human immunodeficiency virus. Journal of Biological Chemistry 263:11760–11767
    [Google Scholar]
  13. Gibson R., Kornfeld S., Schlesinger S. 1981; The effect of oligosaccharide chains of different sizes on the maturation and physical properties of the G protein of vesicular stomatitis virus. Journal of Biological Chemistry 256:456–462
    [Google Scholar]
  14. Gruters R. A., Neefjes J. J., Tersmette M., De Goede R. E. V., Huisman G., Miedema F., Ploegh H. L. 1987; Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature, London 330:74–77
    [Google Scholar]
  15. Hansen J. E. S., Nielsen C. M., Nielsen C., Heegaard P., Mathiesen L. R., Nielsen J. O. 1989; Correlation between carbohydrate structures on the envelope glycoprotein gp120 of HIV-1 and HIV-2 and syncytium inhibition with lectins. AIDS 3:635–641
    [Google Scholar]
  16. Jarvis D. L., Summers M. D. 1989; Glycosylation and secretion of human tissue plasminogen activator in recombinant baculovirus-infected insect cells. Molecular and Cellular Biology 9:214–223
    [Google Scholar]
  17. Karpas A., Fleet G. W. J., Dwek R. A., Petursson S., Namgoong S. K., Ramsden N. G., Jacob G. S., Rademacher T. W. 1988; Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proceedings of the National Academy of Sciences, U.S.A 85:9229–9233
    [Google Scholar]
  18. Kieny M. P., Lathe R., Riviere Y., Doit K., Schmitt D., Girard M., Montagnier L., Lecocq J. P. 1988; Improved antigenicity of the HIV env protein by cleavage site removal. Protein Engineering 2:219–225
    [Google Scholar]
  19. Klatzmann D., McDougal J. S., Maddon P. J. 1990; The CD4 molecule and HIV infection. Immunodeficiency Reviews 2:43–66
    [Google Scholar]
  20. Kornfeld R., Kornfeld S. 1985; Assembly of asparagine-linked oligosaccharides. Annual Review of Biochemistry 5:631–664
    [Google Scholar]
  21. Kozarsky K., Penman M., Basiripour L., Haseltine W., Sodroski J., Krieger M. 1989; Glycosylation and processing of the human immunodeficiency virus envelope protein. Journal of Acquired Immune Deficiency Syndromes 2:163–169
    [Google Scholar]
  22. Lifson J., Coutre S., Huang E., Engleman E. 1986; Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion. Journal of Experimental Medicine 64:2101–2120
    [Google Scholar]
  23. McCune J., Rabin L. B., Feinberg M. B., Lieberman M., Kosek J. C., Reyes G. R., Weissman I. L. 1989; Endoproteolytic cleavage of gpl60 is required for the activation of human immunodeficiency virus. Cell 53:55–67
    [Google Scholar]
  24. Matthews T. J., Weinhold K. J., Lyerly H. K., Langlois A. J., Wigzel H., Bolognesi D. 1987; Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gpl20 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proceedings of the National Academy of Sciences, U.S.A. 84:5424–5428
    [Google Scholar]
  25. Mizuochi T., Spellman M. W., Larkin M., Solomon J., Basal L. J., Feizi T. 1988; Carbohydrate structures of the human immunodeficiency virus (HIV) recombinant envelope glycoprotein E. Fenouillet and J.-C. Gluckman gp120 produced in Chinese hamster ovary cells. Biochemical Journal 254:599–603
    [Google Scholar]
  26. Meloen R. H., Liskamp R. M., Goudsmit J. 1989; Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity. Journal of General Virology 70:1505–1512
    [Google Scholar]
  27. Montefiori D. C., Robinson W. E., Mitchell W. M. 1988; Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, U.S.A. 85:9248–9252
    [Google Scholar]
  28. Morikawa Y., Moore J. P., Jones I. M. 1990a; HIV-1 envelope protein gpl20 expression by secretion in E. coli: assessment of CD4 binding and use in epitope mapping. Journal of Virological Methods 29:105–114
    [Google Scholar]
  29. Morikawa Y., Overton H. A., Moore J. P., Wilkinson A. J., Brady R. L., Lewis S., Jones I. M. 1990b; Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro . AIDS Research and Human Retroviruses 6:765–773.
    [Google Scholar]
  30. Olden K., Bernard B. A., Humphries M. J., Yeo T. K., White S. L., Newton S. A., Bade H. C., Parent J. B. 1985; Function of glycoprotein glycans. Trends in Biochemical Sciences February 78–81
    [Google Scholar]
  31. Pal R., Hoke G. M., Sarngadharan M. G. 1989a; Role of oligosaccharides in the processing and maturation of envelope glycoproteins of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, U.S.A 86:3384–3388
    [Google Scholar]
  32. Pal R., Kalyanaraman V. S., Hoke G. M., Sarngadharan M. G. 1989a; Processing and secretion of envelope glycoproteins of HIV-1 in the presence of trimming glucosidase inhibitor deoxynojirimycin. Intervirology 30:27–35
    [Google Scholar]
  33. Parry N., Fox G., Rowlands D., Brown F., Fry E., Acharya R., Logan D., Stuart D. 1990; Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature, London 347:569–572
    [Google Scholar]
  34. Robinson E. R., Montefiori D. C., Mitchell W. M. 1987; Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 pathogenesis. AIDS Research and Human Retroviruses 3:265–281
    [Google Scholar]
  35. Skerra A., Pluckthun A. 1988; Assembly of a functional immunoglobulin Fv fragment in Escherichia coli . Science 240:1038–1041
    [Google Scholar]
  36. Tarentino A. L., Trimble R. B., Plummer T. H. 1989; Enzymatic approaches for studying the structure, synthesis, and processing of glycoproteins. Methods in Cell Biology 32:111–139
    [Google Scholar]
  37. Tilley S., Honnen W., Racho M., Hilgartner M., Pinter A. 1991; Human monoclonal antibodies against the putative CD4 binding site and the V3 loop of HIV gp 120 act in concert to neutralize virus. Abstract MA 70. VII International Conference on AIDS. Florence June 16–21
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-72-8-1919
Loading
/content/journal/jgv/10.1099/0022-1317-72-8-1919
Loading

Data & Media loading...

Most cited Most Cited RSS feed